Building Your Path to Digital Therapeutics Coverage
A practical guide for manufacturers preparing for payor review
Conventional wisdom says there is no real path to insurance coverage for digital therapeutics. That belief is understandable. Many DTx products enter the market without a familiar coding, coverage, and payment pathway, and many payors do not yet have policies designed for the category. Early cases are therefore evaluated individually and often begin with an experimental and investigational position.
Although this uncertainty can look like a dead end, it does not mean there is no path to coverage. It means your commercial and market access teams must build that path case by case. The barriers tend to repeat, and once your team understands where they come from, it can begin preparing for them long before your first payor review.
Why Coverage Feels Different
If your leadership team comes from technology, that background is a real asset. It brings product instincts and a builder's speed that healthcare companies often lack. The adjustment comes when your product enters the payor environment, where progress follows a different clock and a different set of rules.
FDA review gives your team a defined regulatory process. Coverage development does not offer the same predictable pathway. It proceeds case by case as payors evaluate the evidence presented for specific patients and covered populations.
This distinction matters because FDA and payors are answering different questions. FDA determines whether your product meets the regulatory standard for its pathway. Payors consider whether it is medically necessary, how its clinical value compares with available alternatives, and whether the evidence supports coverage for their members. Clearance or authorization is therefore an essential milestone, but it is the beginning of the coverage journey, not the end.
How your product is used also shapes that journey. Prescribers need a clear clinical use case, a workable workflow, and confidence that patients can access your product. If your digital therapeutic is episodic, with a defined beginning, middle, and end, it generally presents a clearer coverage story. Together, these considerations shape the access model your product will need. The earlier your commercial and market access teams plan for them, the sooner they can begin building a credible path to coverage.
The Experimental and Investigational Trap
Those differences often become visible when your first cases reach the payor. Your team may face an early wave of experimental and investigational denials with limited proven strategies for converting individual denials into approvals or approvals into broader policy change. Volume alone will not help if cases are worked inconsistently or stop at the first denial. A request for a medical policy will also rarely gain traction without a record of favorable case decisions and evidence of medical necessity.
When early cases are submitted without a fully developed strategy, denials can quickly become the pattern your team is forced to reverse. That is why the strategic work needs to happen before the first submission. Your team must identify the strongest initial cases, anticipate the issues each payor is likely to raise, assemble the clinical evidence and medical necessity rationale, and define the appeal pathway in advance. The objective is not simply to overturn one denial. It is to establish favorable outcomes that can become the foundation for the cases that follow.
The Costly Shortcut of Bypassing the Payor
An early wave of denials can make a cash pay or patient assistance option feel like the fastest solution. It can solve immediate access, but if coverage is never requested, the payor sees neither the demand nor the evidence behind those cases. The goal is not to delay patient support. Your access model should pair timely access with a deliberate coverage process by submitting eligible cases, appealing supported denials, and capturing outcomes your team can use in future reviews.
What This Looks Like for Your Team
Building coverage starts before the first case is submitted. Your initial cases establish the record that later cases will either reinforce or have to overcome. Your team should therefore select and prepare them with likely payor objections in mind, support each case with complete clinical documentation, and map the review and appeal path before submission.
A favorable outcome helps the patient in front of you and gives your team a model for the cases that follow. Your team should capture the evidence presented, the medical necessity rationale, the payor issue addressed, and what ultimately moved the decision. Applying those insights consistently allows later cases to strengthen the emerging coverage story.
Over time, those outcomes create a body of evidence specific to each payor. Your team can use that evidence to strengthen future submissions, address recurring objections, and support a broader policy conversation. Bridge or assistance programs can maintain timely patient access while the coverage strategy develops.
You should expect this work to take time, persistence, and specialized expertise. Coverage decisions are built on evidence, and your evidence base grows one patient, one appeal, and one payor decision at a time. If your team commits to the process, you can replace a stack of disconnected denials with a credible and increasingly repeatable coverage story.
A Coverage Model Built for the Category
Your coverage strategy cannot simply copy a familiar pharmaceutical commercialization model. It must reflect how digital therapeutics are evaluated, prescribed, accessed, and reimbursed.
Coverage will not emerge from a single meeting, policy request, or successful appeal. Your evidence base grows as your team works cases consistently, learns from payor objections, and applies those insights to the next submission.
Your path to coverage may not be paved, but it can be built one case, one appeal, one precedent, and one payor policy at a time.
